Skip to main content

Decode Shares Sink 11.7 Percent On Higher Q1 Loss

NEW YORK, May 2 (GenomeWeb News) - Shares in Decode Genetics were down 11.65 percent, or $.89, at $6.75 in mid-afternoon trading after the company said first-quarter losses swelled 20 percent year over year.

 

As GenomeWeb News reported this morning, Decode said total revenues for the three months ended March 31 increased approximately 6-percent though net loss swelled to $20.3 million from $16.9 million in the year-ago period.

 

Decode attributed the increase to higher R&D costs related to clinical trials and preclinical development work in the company's lead drug-development programs.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.